UK MHRA nod for Sereflo breathes fresh life into Cipla, is up 5 %

Mumbai based global generic pharmaceuticals major, Cipla in an exchange filing on Friday, December 23, 2016 informed of the company receiving final approval from UK MHRA for its leading MDI product, Sereflo.

Sereflo is a generic equivalent to GlaxoSmithKline’s Seretide inhalers and are recommended for Asthma treatment. UK sales of the drug is estimated to be approximately USD 278 million for the 12-month period ending June 2016, according to IMS Health.

Cipla plans to launch the drug in the UK market in Q4 of the current financial year.

Commenting on the approval, Umang Vohra, MD and Global CEO Cipla, said, “We are extremely pleased with the approval of Sereflo in the UK. This is a testament of Cipla’s relentless efforts in the respiratory field for over a decade. This reinforces Cipla’s commitment to make a difference in the life of patients with its innovative products. Sereflo will help patients with moderate to severe asthma breathe better.”

Reacting to the approval news, stock of Cipla jumped more than 5 per cent intra-day before closing with the gains of 3.6 per cent at Rs 581.95 on NSE.